GLP-1 Drugs lawsuit update

Verified snapshot

The facts that anchor this dossier

The federal GLP-1 litigation is now two different proceedings—one for alleged gastrointestinal injuries and another for alleged NAION vision loss. Here is the clean, source-based map of both dockets, the labels, and the unsettled science.

GI proceeding

MDL 3094

Eastern District of Pennsylvania; 3,848 pending actions as of July 1, 2026.

Vision proceeding

MDL 3163

A separate docket for alleged non-arteritic anterior ischemic optic neuropathy, also before Judge Karen S. Marston.

MDL 3094 scope

GI injuries

The transfer order identifies alleged gastroparesis, ileus, intestinal obstruction or pseudo-obstruction, and other gastrointestinal injuries.

FDA label context

Delayed gastric emptying

Current semaglutide labels describe delayed gastric emptying and significant gastrointestinal warnings; product-specific wording matters.

What counts cannot show

No payout forecast

Filing totals do not establish causation, claim validity, settlement timing, or individual value.

Documented chronology

How the litigation reached this point

Start with the split: GI claims and vision claims are not one docket

The phrase 'GLP-1 lawsuit' now hides two distinct federal proceedings. MDL 3094 concerns alleged gastrointestinal injuries. Its transfer order named Ozempic, Wegovy, Rybelsus, Trulicity, and Mounjaro and described allegations involving gastroparesis, ileus, intestinal obstruction or pseudo-obstruction, and other GI injury. MDL 3163, created in December 2025, concerns alleged non-arteritic anterior ischemic optic neuropathy, or NAION, involving a defined set of GLP-1 products. Both are before Judge Karen S. Marston, but they retain different master dockets, injury questions, and schedules.

That distinction is more than housekeeping. Evidence about gastric motility does not establish an optic-nerve claim, and an observational vision study does not prove gastroparesis. A reliable update names the drug, the alleged injury, and the docket. Any page that rolls every adverse event into one settlement counter is obscuring the legal and scientific questions the courts are actually managing.

What current labels say about gastrointestinal effects

Semaglutide labels state that the medicine delays gastric emptying. The 2025 Ozempic label lists postmarketing reports that include ileus, intestinal obstruction, and severe constipation including fecal impaction. The 2026 Wegovy label says severe gastrointestinal adverse reactions have occurred, that Wegovy is not recommended in patients with severe gastroparesis, and that delayed gastric emptying may affect absorption of oral medicines. Label language differs by product and indication, so it should be read product by product rather than generalized across an entire drug class.

A postmarketing report is not a controlled incidence estimate and cannot establish that a drug caused the event in the reporter. Conversely, the presence of a known pharmacologic effect such as delayed emptying does not decide whether a warning was legally adequate at a particular time. Those gaps—mechanism, incidence, diagnosis, labeling history, and individual medical proof—are central to the litigation.

The emerging research needs disciplined interpretation

A 2025 retrospective MarketScan cohort of people with obesity and without pre-existing type 2 diabetes compared semaglutide with bupropion-naltrexone and sleeve gastrectomy. The authors reported higher coded gastroparesis risk in the semaglutide group after adjustment. This is useful real-world evidence, but claims databases can misclassify exposure and diagnosis, residual confounding remains possible, and comparison groups receive very different treatments. It supports further inquiry; it is not an individual causation test.

For vision claims, MDL 3163 began with 21 actions and nine reported related actions. The JPML identified common questions about development, testing, regulatory history, labeling, and alleged capacity to cause NAION. The court's Science Day order expressly framed the session as an objective educational overview. Presentations at Science Day are not testimony, findings, or a ruling that one side's scientific position is correct.

What is happening procedurally in MDL 3094

The GI docket has moved into structured merits work. The court has master pleadings, a direct-filing process, plaintiff fact sheets, non-expert deposition protocols, electronic discovery, and briefing schedules for cross-cutting issues. In April 2026, Case Management Order 32 set dates for Rule 702 and summary-judgment briefing and a September 2026 expert hearing. A schedule can change by later order, so the official court page should be checked before treating any future date as fixed.

Plaintiff fact sheets collect medication, medical, and other case-specific information. They are discovery tools for filed cases, not a public qualification quiz. Similarly, a direct-filing order is an administrative convenience and expressly does not concede jurisdiction or venue. These distinctions matter because procedural efficiency is often misreported as a ruling on liability.

A practical way to follow this litigation

First identify the exact medication and alleged injury. Then check the corresponding court's orders and the FDA label version relevant to the period of use. For GI issues, medical records may distinguish transient nausea or constipation—common labeled effects—from a clinician-diagnosed motility disorder or obstruction. For a vision allegation, ophthalmology records and diagnosis timing carry different significance. Only a treating professional should interpret symptoms or recommend starting, stopping, or changing treatment.

Finally, resist dollar estimates built from docket size. MDL 3094's 3,848 pending cases as of July 1, 2026 say nothing about the proof in any one action. There is no official public matrix establishing universal values, and this dossier does not determine eligibility, deadlines, causation, or legal merit. Those questions turn on evolving orders, governing law, records, and individual facts.

Reader questions

Frequently asked questions